Clinical Trial Update: The Effect of Intermittent Rifampicin on Raltegravir [Phase 1]

View source ↗

Summary

A Phase 1 study assessed how intermittent rifampicin affects raltegravir exposure, in participants with HIV and tuberculosis. The trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection
• Tuberculosis

Drugs mentioned

• Isentress (Raltegravir)
• Rifadin (rifampin)

Snippet

Sponsor: Helen Reynolds | Conditions: HIV, Tuberculosis | Phase 1 | Status: COMPLETED